Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review

Dorene M Rentz, Mario A Parra Rodriguez, Rebecca Amariglio, Yaakov Stern, Reisa Sperling, Steven Ferris

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.
Original languageEnglish
Number of pages10
JournalAlzheimer's research & therapy
Volume5
Issue number6
DOIs
Publication statusPublished - 21 Nov 2013

Keywords

  • mild cognitive impairment
  • default mode network
  • cerebral spinal fluid
  • cognitive reserve
  • pattern separation
  • neuropsychological
  • Alzheimer’s disease

Fingerprint Dive into the research topics of 'Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review'. Together they form a unique fingerprint.

  • Cite this